Evelyn Partners Asset Management Ltd Reduces Position in AbbVie Inc. $ABBV

Evelyn Partners Asset Management Ltd decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 83.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,488 shares of the company’s stock after selling 7,504 shares during the period. Evelyn Partners Asset Management Ltd’s holdings in AbbVie were worth $276,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. AXQ Capital LP grew its position in shares of AbbVie by 21.4% in the second quarter. AXQ Capital LP now owns 9,978 shares of the company’s stock valued at $1,852,000 after purchasing an additional 1,762 shares in the last quarter. Cooper Haims Advisors LLC boosted its stake in AbbVie by 2.9% during the second quarter. Cooper Haims Advisors LLC now owns 3,020 shares of the company’s stock worth $560,000 after buying an additional 86 shares during the last quarter. Journey Strategic Wealth LLC boosted its stake in AbbVie by 42.3% during the second quarter. Journey Strategic Wealth LLC now owns 23,052 shares of the company’s stock worth $4,279,000 after buying an additional 6,856 shares during the last quarter. MAI Capital Management grew its holdings in AbbVie by 3.8% in the 2nd quarter. MAI Capital Management now owns 539,434 shares of the company’s stock valued at $100,130,000 after buying an additional 19,996 shares in the last quarter. Finally, Hillsdale Investment Management Inc. increased its stake in shares of AbbVie by 954.3% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 18,008 shares of the company’s stock worth $3,343,000 after acquiring an additional 16,300 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of ABBV opened at $236.12 on Friday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The stock has a market cap of $417.31 billion, a PE ratio of 112.44, a P/E/G ratio of 1.42 and a beta of 0.50. The firm has a 50-day simple moving average of $226.81 and a two-hundred day simple moving average of $205.22. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ABBV. BMO Capital Markets boosted their price target on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, September 12th. Piper Sandler restated an “overweight” rating and set a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Daiwa America raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Finally, Morgan Stanley raised their price target on shares of AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.